معرفی
Xiaoling Li is an Associate Research Scientist in the Department of Urology at Yale School of Medicine. She is affiliated with the Mu Lab, focusing on cancer biology and molecular mechanisms of therapy resistance. Her research interests include prostate cancer progression, drug resistance pathways, and the role of epigenetic and ubiquitin-proteasome systems in tumor heterogeneity.
Dr. Li’s work combines experimental oncology with genomic approaches to uncover how tumors evade treatments like androgen receptor (AR)-targeted therapies. Collaborations with Ping Mu and other Yale researchers have led to breakthroughs in understanding mechanisms such as SYNCRIP loss driving APOBEC mutagenesis and CHD1 deficiency promoting chromatin dysregulation. She also investigates YAP-driven chemoresistance in lung cancer and CAF plasticity’s role in prostate cancer progression.
Her publications span high-impact journals like Cancer Cell, Nature Cancer, and Oncogene, with a focus on translating molecular findings into therapeutic strategies. Current projects aim to exploit ubiquitination pathways and tumor microenvironment dynamics to overcome treatment resistance.
